

Supplementary Online Content

Ker CC, Chen JL, Chen YS: Trends of treatments of hepatocellular carcinoma in recent 3-decade based on the Top-100 influential articles from Taiwan. E-Da Med J 2023;10:34-46. doi:10.6966/EDMJ.202312_10(4).0004.

eTable 1. List of Taiwan Top-100 articles searching from Web of Science Core Database and selected based on the ranking of times cited in each year published from Taiwan.

This supplementary material has been provided by the authors to give readers additional information about their work.

Table 1. List of Taiwan Top-100 articles searching from Web of Science Core Database and selected based on the ranking of times cited in each year published from Taiwan.

ID no	Author	Article title	Journal. year;vol:page-page	Times cited, WOS core
1	Haieh MY	Treatment of hepatocellular carcinoma by transcatheter arterial chemo-embolization and analysis of prognostic factors	Cancer Chemotherapy Pharmacology. 1992;31:S82-85	32
2	Chiu JH	Can determination of the proliferative capacity of the nontumor portion predict the risk of tumor recurrence in the liver remnant after resection of human hepatocellular-carcinoma	Hepatology. 1993;18:96-102	49
3	Chang JM	Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular-carcinoma – a randomized controlled-study	Cancer. 1994;74:2449-2453	130
4	Wu CC	Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular-carcinoma - a reappraisal	British journal of Surgery. 1995;82:122-126	179
5	Lee CS	Long-term outcome after surgery for asymptomatic small hepatocellular carcinoma	British journal of Surgery. 1996;83:330-333	55
6	Chau GY	Prognostic significance of surgical margin in hepatocellular carcinoma resection: An analysis of 165 Childs' A patients	Journal of Surgical Oncology. 1997;66:122-126	79
7	Lee NH	Surgical treatment and outcome in patients with a hepatocellular carcinoma greater than 10 cm in diameter	British journal of Surgery. 1998;85:1654-1657	59
8	Huang YH	Supportive treatment, resection and transcatheter arterial chemoembolization in resectable hepatocellular carcinoma: an analysis of survival in 419 patients	European journal of Gastroenterology & Hepatology. 1999;11:315-321	47
9	Tsai TJ	Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma	Surgery. 2000;127:603-608	211
10	Cheng SB	Liver resection for hepatocellular carcinoma in patients with end-stage renal failure	Journal of Surgical Oncology. 2001;78:241-246	29
11	Yeh CN	Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis	Journal of Surgical Oncology. 2002;81:195-202	156
12	Lee WC	Estimation of prognosis after hepatectomy for hepatocellular carcinoma	British journal of Surgery. 2002;89:311-316	55
13	Hsu C	Low-dose thalidomide treatment for advanced hepatocellular carcinoma	Oncology. 2003;65:242-249	77
14	Chen MF	Prognostic factors after resection for hepatocellular carcinoma in non-cirrhotic livers: univariate and multivariate analysis	World journal of surgery. 2003;27:443-447	68
15	Lin SM	Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma <= 4cm	Gastroenterology. 2004;127:1714-1723	480
16	Liu MT	Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization	Japanese journal of clinical oncology. 2004;34:532-539	77
17	Huang GT	Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma - A prospective study	Annals of Surgery. 2005;242:36-42	158
18	Lee WC	Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells - A clinical trial	Journal of Immunotherapy. 2005;28:496-504	139

Continued on next page

Table 1. List of Taiwan Top-100 articles searching from Web of Science Core Database and selected based on the ranking of times cited in each year published from Taiwan. (continued)

19	Yu HC	Factors for early tumor recurrence of single small hepatocellular carcinoma after percutaneous radiofrequency ablation therapy	World journal of Gastroenterology. 2005;11:1439-1444	65
20	Lin CC	Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial	Investigational New Drugs. 2006;25:77-84	93
21	Chung YL	Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: Implications for radiotherapy of hepatocellular carcinoma	Clinical Cancer Rresearch. 2006;12:2706-2715	81
22	Hsu HC	Three-dimensional conformal radiotherapy for the treatment of arteriovenous shunting in patients with hepatocellular car	British journal of Radiology. 2007;80:38-42	26
23	Kao JT	P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection	Liver International. 2007;27:772-781	28
24	Chen HY	Laparoscopic liver surgery for patients with hepatocellular carcinoma	Annals of Surgical Oncology. 2008;15:800-806	112
25	Wong SN	Combined percutaneous radiofrequency ablation and ethanol injection for hepatocellular carcinoma in high-risk locations	American Journal of Roentgenology. 2008;190:W187-195	64
26	Concejero A	Living donor liver transplantation for hepatocellular carcinoma: a single-center experience in Taiwan	Transplantation. 2008;85:398-406	64
27	Cheng AL	Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial	Lancet Oncology. 2009;10:25-34	3,945
28	Ho MC	Liver resection improves the survival of patients with multiple hepatocellular carcinomas	Annals of Surgical Oncology. 2009;16:848-855	90
29	Wang CC	Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma	Annals of Surgical Oncology. 2009;16:1832-1842	109
30	Yang TS	A randomized phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients	British Journal of Cancer. 2010;103:954-960	111
31	Hsu CH	Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma	British Journal of Cancer. 2010;102:981-986	108
32	Shao YY	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma	Cancer. 2010;116:4590-4596	132
33	Hung HH	Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas	Clinical Gastroenterology and Hepatology. 2011;9:79-86	113
34	Hsu CY	Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil	Journal of Hepatology. 2011;55:858-865	95
35	Kao WY	Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index	European journal of Gastroenterology & Hepatology. 2011;23:528-536	57

Continued on next page

Table 1. List of Taiwan Top-100 articles searching from Web of Science Core Database and selected based on the ranking of times cited in each year published from Taiwan. (continued)

36	Hsu CY	Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis	Liver Transplantation. 2011;17:556-566	47
37	Feng YH	Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma	Medical Oncology. 2011;28:1080-1088	20
38	Wu CY	Association between nucleoside analogues and risk of hepatitis b virus-related hepatocellular carcinoma recurrence following liver resection	JJAMA-Journal of the American Medical Association. 2012;308:1906-1913	633
39	Wang JH	Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma	Journal of Hepatology. 2012;56:412-418	214
40	Cheng AL	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial	European journal of Cancer. 2012;48:1452-1465	187
41	Lau WY	Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres	International journal of Radiation Oncology Biology Physics. 2012;82:401-407	144
42	Huang WY	Stereotactic body radiation therapy in recurrent hepatocellular carcinoma	International journal of Radiation Oncology Biology Physics. 2012;84:355-361	129
43	Llovet JM	Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study	Journal of Clinical Oncology. 2013;31:3509-3516	429
44	Qin SK	Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia	Journal of Clinical Oncology. 2013;31:3501-3508	280
45	Toh HC	Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma	Cancer. 2013;119:380-387	87
46	Finn RS	Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma	Journal of Hepatology. 2013;59:1271-1277	61
47	Hsu CH	Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study	Oncology. 2013;85:44-52	39
48	Ho CM	Analysis of the risk factors of untransplantable recurrence after primary curative resection for patients with hepatocellular carcinoma	Annals of Surgical Oncology. 2013;20:2526-2533	12
49	Zhu AX	Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib the EVOLVE-1 randomized clinical trial	JAMA-journal of the American Medical Association. 2014;312:57-67	408
50	Kudo M	Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial	Hepatology. 2014;60:1697-1707	198
51	Chen SW	Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma	International journal of Radiation Oncology Biology Physics. 2014;88:1041-1047	90

Continued on next page

Table 1. List of Taiwan Top-100 articles searching from Web of Science Core Database and selected based on the ranking of times cited in each year published from Taiwan. (continued)

52	Liu PH	Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis	Annals of Surgical Oncology. 2014;21:1825-1833	78
53	Lim HY	A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma	Clinical Cancer Research. 2014;20:5976-5985	76
54	Cainap C	Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial	Journal of Clinical Oncology. 2015;33:172-179	395
55	Kang YK	Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma	Annals of Oncology. 2015;26:2457-2463	63
56	Lin TH	High serum transforming growth factor-beta 1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib	Clinical Cancer Research. 2015;21:3678-3684	63
57	Liu YS	Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma	Korean journal of Radiology. 2015;16:125-132	34
58	Lin CC	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein thrombosis: Impact of early response to 4 weeks of treatment	Liver Cancer. 2015;4:228-240	32
59	Lee YH	Radiofrequency ablation is better than surgical resection in patients with hepatocellular carcinoma within the Milan criteria and preserved liver function a retrospective study using propensity score analyses	Journal of Clinical Gastroenterology. 2015;49:242-249	27
60	Lencioni R	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial	Journal of Hepatology. 2016;64:1090-1098	372
61	Liu PH	Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma \leq 2 cm in a propensity score model	Annals of Surgery. 2016;263:538-545	105
62	Abou-Alfa GK	Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma	Journal of Hepatology. 2016;65:289-295	63
63	Lin CC	The effectiveness of multiple electrode radiofrequency ablation in patients with hepatocellular carcinoma with lesions more than 3 cm in size and Barcelona clinic liver cancer stage A to B2	Liver Cancer. 2016;5:8-20	43
64	Lee YL	Body mass index and cholesterol level predict surgical outcome in patients with hepatocellular carcinoma in Taiwan - a cohort study	Oncotarget. 2016;7:22948-22959	28
65	Ali MA	Impact of pathological features of primary hepatocellular carcinoma on the outcomes of intrahepatic recurrence management: single center experience from Southern Taiwan	HPB. 2016;18:851-860	5
66	El-Khoueiry AB	Nivolumab in patients with advanced hepatocellular carcinoma (checkmate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial	Lancet. 2017;389:2492-2502	1,967

Continued on next page

Table 1. List of Taiwan Top-100 articles searching from Web of Science Core Database and selected based on the ranking of times cited in each year published from Taiwan. (continued)

67	Kelley RK	Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study	Annals of Oncology. 2017;28:528-534	94
68	Chen PD	Robotic versus open hepatectomy for hepatocellular carcinoma: a matched comparison	Annals of Surgical Oncology. 2017;24:1021-1028	64
69	Kao WY	Hepatocellular carcinoma: nomograms based on the albumin-bilirubin grade to assess the outcomes of radiofrequency ablation	Radiology. 2017;285:670-680	59
70	Zhu AX	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma analysis of REACH trial results by Child-Pugh score	JAMA Oncology. 2017;3:235-243	47
71	Pardo F	The post-SIR-spheres surgery study (P4S): retrospective analysis of safety following hepatic resection or transplantation in patients previously treated with selective internal radiation therapy with yttrium-90 resin microspheres	Annals of Surgical Oncology. 2017;24:2465-2473	29
72	Chow PKH	Sirvenib: selective internal radiation therapy versus sorafenib in Asia-pacific patients with hepatocellular carcinoma	Journal of Clinical Oncology. 2018;36:1913-1921	283
73	Finn RS	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial	Journal of Hepatology. 2018;69:353-358	171
74	Abou-Alfa GK	Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma	Annals of Oncology. 2018;29:1402-1408	99
75	Lim HY	Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular carcinoma	Clinical Cancer Research. 2018;24:4650-4661	28
76	Dai CY	Impact of tumor size on the prognosis of hepatocellular carcinoma in patients who underwent liver resection	Journal of the Chinese Medical Association. 2018;81:155-163	26
77	Wang TH	Combined Yttrium-90 microsphere selective internal radiation therapy and external beam radiotherapy in patients with hepatocellular carcinoma: From clinical aspects to dosimetry	PLoS One. 2018;13:e0190098	11
78	Zhu AX	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial	Lancet Oncology.2019;20:282-296	638
79	Yau T	Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis	Journal of Hepatology. 2019;71:543-552	90
80	Pinyol R	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial	Gut. 2019;68:1065-1075	82
81	Kim RD	First-in-human phase I study of fisogatinib (BLU-554) validates Aberrant FGF19 signaling as a driver event in hepatocellular carcinoma	Cancer Discovery. 2019;9:1696-1707	70

Continued on next page

Table 1. List of Taiwan Top-100 articles searching from Web of Science Core Database and selected based on the ranking of times cited in each year published from Taiwan. (continued)

82	Moehler M	Vaccinia-based oncolytic immunotherapy pexastimogene devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter phase IIb trial (TRAVERSE)	Oncoimmunology. 2019;8: 1615817	38
83	Chadha AS	Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma	Radiotherapy and Oncology. 2019;133:54-61	18
84	Lee IC	A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma	Liver International. 2019;39:1704-1712	34
85	Yau T	Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib the checkmate 040 randomized clinical trial	JAMA Oncology. 2020;6:e204564	214
86	Lee MS	Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study	Lancet Oncology. 2020;21:808-820	143
87	Sangro B	Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma	Journal of Hepatology. 2020;73:1460-1469	67
88	Kim N	Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma	Journal of Hepatology. 2020;73:121-129	46
89	Hack SP	Imbrave 050: a phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation	Future Oncology. 2020;16:975-989	42
90	Bang YJ	Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)	European journal of Cancer. 2020;137:272-284	31
91	Lee PC	Predictors of response and survival in immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma	Cancers. 2020;12:182-196	29
92	Kelley RK	Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study	Journal of Clinical Oncology. 2021;39:2991-3001	28
93	Galle PR	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (imbrave150): an open-label, randomized, phase 3 trial	Lancet Oncology. 2021;22:991-1001	21
94	Kudo M	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2	JHBP Reports. 2021;3:100215	10
95	Hsu CL	Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma	Liver Cancer. 2021;10:346-359	8
96	Lai Q	Evaluation of the intention-to-treat benefit of living donation in patients with hepatocellular carcinoma awaiting a liver transplant	JAMA Surgery. 2021;156	6
97	Kudo M	Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: a subgroup analysis of Asian patients in the phase 3 KEYNOTE-240 trial	Liver Cancer. 2021;10:275-284	6

Continued on next page

Table 1. List of Taiwan Top-100 articles searching from Web of Science Core Database and selected based on the ranking of times cited in each year published from Taiwan. (continued)

98	Lee IC	Predictors of long-term recurrence and survival after resection of HBV-related hepatocellular carcinoma: the role of HBsAg	American journal of Cancer Research. 2021;11:3711-3725	6
99	Pinato DJ	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice	European journal of Cancer. 2021;157:140-152	5
100	Su CM	Comparison of anatomic and non-anatomic resections for very early-stage hepatocellular carcinoma: The importance of surgical resection margin width in non-anatomic resection	Surgical Oncology-Oxford. 2021;36:15-22	4